Extended oral antibiotics have been found efficient in reducing the rate of prosthetic joint infections which is one of the common complications and etiologies of implant failure after joint replacement surgeries. Antibiotics is an antimicrobial substance that fights against bacterial infections and seldom with protozoan infection, but not viral infections. The rise in number of total joint (knee and hip) arthroplasty linked with increase in advancements in novel therapies is foreseen to encourage the global extended oral antibiotics market in the coming years. Increase in government reimbursement and surge in focus on R&D activities to launch emerging therapies will make a positive impact on the growth of extended oral antibiotics.
COVID-19 Impact analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the extended oral antibiotics market.
Top Impacting Factors
- Increase in cases of cardiovascular diseases, surge in geriatric populations, rise in demand for minimally invasive procedure & advanced cardiovascular treatment and procedures such as balloon angioplasty are the factors that drive the growth of the angioplasty balloons market
- In addition, increase in healthcare expenditure; availability of skilled professionals; collaborations & partnerships between key players to facilitate drug development; rise in R&D activities to improve quality of drugs; launch of novel developed drug in market; and technological development such as imaging technologies, drug-eluting, and cutting balloons are some factors, which boost the market growth for angioplasty balloons
- However, lack of knowledge for proper handling of the device as well as side effects and associated complications hinder the market growth.
- Contrarily, favorable reimbursement policies and support from government for regulatory approval present new pathways in the industry
Market Trends
New product pipeline to flourish the market
Key manufacturers are focusing on investing more in research activities to develop more extended oral antibiotics due to the rise in demand for controlling and preventing prosthetic joint infections.
Nabriva Therapeutics plc is involved in clinical trials to develop extended oral antibiotics. Its compound Lefamulin (IV/Oral) is in Phase I of a clinical trial for the indications including osteomyelitis and prosthetic joint infection.
In addition, other players including Melinta Therapeutics, Inc. and Telephus Medical LLC have their compounds in the pipeline for the treatment.
Key Benefits of the Report
- This study presents the analytical depiction of the extended oral antibiotics industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the extended oral antibiotics market share.
- The current market is quantitatively analyzed to highlight the extended oral antibiotics market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed extended oral antibiotics market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the extended oral antibiotics report
- Which are the leading players active in the extended oral antibiotics market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "Extended oral antibiotics"?
- What is "Extended oral antibiotics" Market prediction in the future?
- Who are the leading global players in the "Extended oral antibiotics" Market?
- What are the current trends and predicted trends?
- What are the key benefits of the "Extended oral antibiotics" Market report?
Extended Oral Antibiotics Market Report Highlights
| Aspects | Details |
 By Drug Type |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | AstraZeneca plc, Bristol-Myers Squibb Co., GlaxoSmithKline plc, Novartis AG, Allergan plc, Johnson & Johnson Services Inc., Pfizer Inc., Abbott Laboratories, Sanofi SA, Merck & Co. |
Loading Table Of Content...
